FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:997-1003 March 10, 2005 Number 10 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by DeAngelis, L. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Epigenetic silencing of the MGMT (O⁶-methylguanine–DNA methyltransferase) DNA-repair gene by promoter methylation compromises DNA repair and has been associated with longer survival in patients with glioblastoma who receive alkylating agents.

Methods We tested the relationship between MGMT silencing in the tumor and the survival of patients who were enrolled in a randomized trial comparing radiotherapy alone with radiotherapy combined with concomitant and adjuvant treatment with temozolomide. The methylation status of the MGMT promoter was determined by methylation-specific polymerase-chain-reaction analysis.

Results The MGMT promoter was methylated in 45 percent of 206 assessable cases. Irrespective of treatment, MGMT promoter methylation was an independent favorable prognostic factor (P<0.001 by the log-rank test; hazard ratio, 0.45; 95 percent confidence interval, 0.32 to 0.61). Among patients whose tumor contained a methylated MGMT promoter, a survival benefit was observed in patients treated with temozolomide and radiotherapy; their median survival was 21.7 months (95 percent confidence interval, 17.4 to 30.4), as compared with 15.3 months (95 percent confidence interval, 13.0 to 20.9) among those who were assigned to only radiotherapy (P=0.007 by the log-rank test). In the absence of methylation of the MGMT promoter, there was a smaller and statistically insignificant difference in survival between the treatment groups.

Conclusions Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.

Source Information

From the Laboratory of Tumor Biology and Genetics, Department of Neurosurgery (M.E.H., A.-C.D., M.-F.H., N.T.), the Departments of Radiotherapy (R.O.M.) and Neuropathology (R.C.J.), and the Multidisciplinary Oncology Center (R.S.), University Hospital Lausanne, Lausanne; the Department of Neurosurgery, University Hospital Geneva, Geneva (N.T.); the National Center of Competence in Research Molecular Oncology, Swiss Institute for Experimental Cancer Research, Epalinges (M.E.H.); and the Department of Neurosurgery, Inselspital, Bern (L.M.) — all in Switzerland; the Data Center, European Organisation for Research and Treatment of Cancer, Brussels (T.G.); the Department of Neurology, University of Tübingen, Tübingen (M.W.), and the Department of Neurology, University of Regensburg, Regensburg (P.H.) — both in Germany; the Division of Neuropathology, University Hospital Rotterdam, Rotterdam (J.M.K.), and University Medical Center, Utrecht (J.E.C.B.) — both in the Netherlands; the Institute of Neurology, Medical University of Vienna, Vienna, (J.A.H.); and Princess Margaret Hospital, Toronto (W.M.), and the University of Calgary, Calgary, Alta. (J.G.C.) — both in Canada.

Address reprint requests to Dr. Hegi at the Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital (CHUV), BH19-110, 1011 Lausanne, Switzerland, or at monika.hegi{at}chuv.hospvd.ch.

Full Text of this Article

Related Letters:

Treatment of Brain Tumors
Paulino A. C., Teh B. S., Sadeh M., Seiter K., Ashby L., LaRocca R., Ryken T., Aiken R. D., Rutkowski S., Ottensmeier H., Pietsch T., Stupp R., Hegi M. E., DeAngelis L. M.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:2350-2353, Jun 2, 2005. Correspondence

This article has been cited by other articles:

• Sigmond, J., Honeywell, R. J., Postma, T. J., Dirven, C. M. F., de Lange, S. M., van der Born, K., Laan, A. C., Baayen, J. C. A., Van Groeningen, C. J., Bergman, A. M., Giaccone, G., Peters, G. J. (2008). Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. Ann Oncol 0: mdn543v1-mdn543 [Abstract] [Full Text]  
• Schaich, M., Kestel, L., Pfirrmann, M., Robel, K., Illmer, T., Kramer, M., Dill, C., Ehninger, G., Schackert, G., Krex, D. (2008). A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 0: mdn548v1-mdn548 [Abstract] [Full Text]  
• Linnebank, M., Semmler, A., Moskau, S., Smulders, Y., Blom, H., Simon, M. (2008). The methylenetetrahydrofolate reductase (MTHFR) variant c.677C>T (A222V) influences overall survival of patients with glioblastoma multiforme. Neuro Oncol 10: 548-552 [Abstract] [Full Text]  
• Wen, P. Y., Kesari, S. (2008). Malignant Gliomas in Adults. NEJM 359: 492-507 [Full Text]  
• Mason, W. P., Cairncross, J. G. (2008). Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas. Neurology 71: 365-373 [Abstract] [Full Text]  
• Beier, D., Rohrl, S., Pillai, D. R., Schwarz, S., Kunz-Schughart, L. A., Leukel, P., Proescholdt, M., Brawanski, A., Bogdahn, U., Trampe-Kieslich, A., Giebel, B., Wischhusen, J., Reifenberger, G., Hau, P., Beier, C. P. (2008). Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma. Cancer Res. 68: 5706-5715 [Abstract] [Full Text]  
• Hamstra, D. A., Galban, C. J., Meyer, C. R., Johnson, T. D., Sundgren, P. C., Tsien, C., Lawrence, T. S., Junck, L., Ross, D. J., Rehemtulla, A., Ross, B. D., Chenevert, T. L. (2008). Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival. JCO 26: 3387-3394 [Abstract] [Full Text]  
• Colman, H., Aldape, K. (2008). Molecular Predictors in Glioblastoma: Toward Personalized Therapy. Arch Neurol 65: 877-883 [Abstract] [Full Text]  
• Liang, X.-J., Choi, Y., Sackett, D. L., Park, J. K. (2008). Nitrosoureas Inhibit the Stathmin-Mediated Migration and Invasion of Malignant Glioma Cells. Cancer Res. 68: 5267-5272 [Abstract] [Full Text]  
• Iafrate, A. J., Louis, D. N. (2008). "MGMT for pt mgmt": Is Methylguanine-DNA Methyltransferase Testing Ready for Patient Management?. J. Mol. Diagn. 10: 308-310 [Abstract] [Full Text]  
• Vlassenbroeck, I., Califice, S., Diserens, A.-C., Migliavacca, E., Straub, J., Di Stefano, I., Moreau, F., Hamou, M.-F., Renard, I., Delorenzi, M., Flamion, B., DiGuiseppi, J., Bierau, K., Hegi, M. E. (2008). Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma. J. Mol. Diagn. 10: 332-337 [Abstract] [Full Text]  
• Murat, A., Migliavacca, E., Gorlia, T., Lambiv, W. L., Shay, T., Hamou, M.-F., de Tribolet, N., Regli, L., Wick, W., Kouwenhoven, M. C.M., Hainfellner, J. A., Heppner, F. L., Dietrich, P.-Y., Zimmer, Y., Cairncross, J. G., Janzer, R.-C., Domany, E., Delorenzi, M., Stupp, R., Hegi, M. E. (2008). Stem Cell-Related "Self-Renewal" Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma. JCO 26: 3015-3024 [Abstract] [Full Text]  
• Sarkaria, J. N., Kitange, G. J., James, C. D., Plummer, R., Calvert, H., Weller, M., Wick, W. (2008). Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma. Clin. Cancer Res. 14: 2900-2908 [Abstract] [Full Text]  
• Rietschel, P., Wolchok, J. D., Krown, S., Gerst, S., Jungbluth, A. A., Busam, K., Smith, K., Orlow, I., Panageas, K., Chapman, P. B. (2008). Phase II Study of Extended-Dose Temozolomide in Patients With Melanoma. JCO 26: 2299-2304 [Abstract] [Full Text]  
• Geiger, G. A., Fu, W., Kao, G. D. (2008). Temozolomide-Mediated Radiosensitization of Human Glioma Cells in a Zebrafish Embryonic System. Cancer Res. 68: 3396-3404 [Abstract] [Full Text]  
• Plummer, E. R., Calvert, H. (2008). Targeting Poly(ADP-Ribose) Polymerase: A Two-Armed Strategy for Cancer Therapy. aacredbook 2008: 15-22 [Abstract] [Full Text]  
• Esteller, M. (2008). Epigenetics in Cancer. NEJM 358: 1148-1159 [Full Text]  
• Kaloshi, G., Everhard, S., Laigle-Donadey, F., Marie, Y., Navarro, S., Mokhtari, K., Idbaih, A., Ducray, F., Thillet, J., Hoang-Xuan, K., Delattre, J.-Y, Sanson, M. (2008). Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri. Neurology 70: 590-595 [Abstract] [Full Text]  
• Heimberger, A. B., Sun, W., Hussain, S. F., Dey, M., Crutcher, L., Aldape, K., Gilbert, M., Hassenbusch, S. J., Sawaya, R., Schmittling, B., Archer, G. E., Mitchell, D. A., Bigner, D. D., Sampson, J. H. (2008). Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study. Neuro Oncol 10: 98-103 [Abstract] [Full Text]  
• Kil, W. J., Cerna, D., Burgan, W. E., Beam, K., Carter, D., Steeg, P. S., Tofilon, P. J., Camphausen, K. (2008). In vitro and In vivo Radiosensitization Induced by the DNA Methylating Agent Temozolomide. Clin. Cancer Res. 14: 931-938 [Abstract] [Full Text]  
• Sathornsumetee, S., Cao, Y., Marcello, J. E., Herndon, J. E. II, McLendon, R. E., Desjardins, A., Friedman, H. S., Dewhirst, M. W., Vredenburgh, J. J., Rich, J. N. (2008). Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan. JCO 26: 271-278 [Abstract] [Full Text]  
• Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Sathornsumetee, S., Rich, J. N., Quinn, J. A., Lagattuta, T. F., Egorin, M. J., Gururangan, S., McLendon, R., Herndon, J. E. II, Friedman, A. H., Salvado, A. J., Friedman, H. S. (2008). Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma. Neuro Oncol 10: 330-340 [Abstract] [Full Text]  
• Kesari, S., Schiff, D., Henson, J. W., Muzikansky, A., Gigas, D. C., Doherty, L., Batchelor, T. T., Longtine, J. A., Ligon, K. L., Weaver, S., Laforme, A., Ramakrishna, N., Black, P. McL., Drappatz, J., Ciampa, A., Folkman, J., Kieran, M., Wen, P. Y. (2008). Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol 10: 300-308 [Abstract] [Full Text]  
• Assadian, S., Aliaga, A., Del Maestro, R. F., Evans, A. C., Bedell, B. J. (2008). FDG-PET imaging for the evaluation of antiglioma agents in a rat model. Neuro Oncol 10: 292-299 [Abstract] [Full Text]  
• Bock, C., Lengauer, T. (2008). Computational epigenetics. Bioinformatics 24: 1-10 [Abstract] [Full Text]  
• Zalutsky, M. R., Reardon, D. A., Akabani, G., Coleman, R. E., Friedman, A. H., Friedman, H. S., McLendon, R. E., Wong, T. Z., Bigner, D. D. (2008). Clinical Experience with {alpha}-Particle Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6. JNM 49: 30-38 [Abstract] [Full Text]  
• Nagane, M., Kobayashi, K., Ohnishi, A., Shimizu, S., Shiokawa, Y. (2007). Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Protein Expression in Patients with Recurrent Glioblastoma Treated with Temozolomide. Jpn J Clin Oncol 0: hym132v1-10 [Abstract] [Full Text]  
• Alonso, M. M., Gomez-Manzano, C., Bekele, B. N., Yung, W.K. A., Fueyo, J. (2007). Adenovirus-Based Strategies Overcome Temozolomide Resistance by Silencing the O6-Methylguanine-DNA Methyltransferase Promoter. Cancer Res. 67: 11499-11504 [Abstract] [Full Text]  
• Batista, L. F.Z., Roos, W. P., Christmann, M., Menck, C. F.M., Kaina, B. (2007). Differential Sensitivity of Malignant Glioma Cells to Methylating and Chloroethylating Anticancer Drugs: p53 Determines the Switch by Regulating xpc, ddb2, and DNA Double-Strand Breaks. Cancer Res. 67: 11886-11895 [Abstract] [Full Text]  
• Shirahata, M., Iwao-Koizumi, K., Saito, S., Ueno, N., Oda, M., Hashimoto, N., Takahashi, J. A., Kato, K. (2007). Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis. Clin. Cancer Res. 13: 7341-7356 [Abstract] [Full Text]  
• Lefranc, F., Facchini, V., Kiss, R. (2007). Proautophagic Drugs: A Novel Means to Combat Apoptosis-Resistant Cancers, with a Special Emphasis on Glioblastomas. The Oncologist 12: 1395-1403 [Abstract] [Full Text]  
• Broniscer, A., Gururangan, S., MacDonald, T. J., Goldman, S., Packer, R. J., Stewart, C. F., Wallace, D., Danks, M. K., Friedman, H. S., Poussaint, T. Y., Kun, L. E., Boyett, J. M., Gajjar, A., for the Pediatric Brain Tumor Consortium, (2007). Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report. Clin. Cancer Res. 13: 6712-6718 [Abstract] [Full Text]  
• Hoelzinger, D. B., Demuth, T., Berens, M. E. (2007). Autocrine Factors That Sustain Glioma Invasion and Paracrine Biology in the Brain Microenvironment. JNCI J Natl Cancer Inst 99: 1583-1593 [Abstract] [Full Text]  
• Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., Chin, L., DePinho, R. A., Cavenee, W. K. (2007). Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21: 2683-2710 [Abstract] [Full Text]  
• Plummer, E. R., Calvert, H. (2007). Targeting Poly(ADP-Ribose) Polymerase: A Two-Armed Strategy for Cancer Therapy. Clin. Cancer Res. 13: 6252-6256 [Abstract] [Full Text]  
• Vredenburgh, J. J., Desjardins, A., Herndon, J. E. II, Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., Wagner, M., Bailey, L., Bigner, D. D., Friedman, A. H., Friedman, H. S. (2007). Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme. JCO 25: 4722-4729 [Abstract] [Full Text]  
• Pyrko, P., Schonthal, A. H., Hofman, F. M., Chen, T. C., Lee, A. S. (2007). The Unfolded Protein Response Regulator GRP78/BiP as a Novel Target for Increasing Chemosensitivity in Malignant Gliomas. Cancer Res. 67: 9809-9816 [Abstract] [Full Text]  
• Short, S. C., Martindale, C., Bourne, S., Brand, G., Woodcock, M., Johnston, P. (2007). DNA repair after irradiation in glioma cells and normal human astrocytes. Neuro Oncol 9: 404-411 [Abstract] [Full Text]  
• Krex, D., Klink, B., Hartmann, C., von Deimling, A., Pietsch, T., Simon, M., Sabel, M., Steinbach, J. P., Heese, O., Reifenberger, G., Weller, M., Schackert, G., for the German Glioma Network, (2007). Long-term survival with glioblastoma multiforme. Brain 130: 2596-2606 [Abstract] [Full Text]  
• Schiff, D., Brown, P. D., Giannini, C. (2007). Outcome in adult low-grade glioma: The impact of prognostic factors and treatment. Neurology 69: 1366-1373 [Abstract] [Full Text]  
• Lavon, I., Fuchs, D., Zrihan, D., Efroni, G., Zelikovitch, B., Fellig, Y., Siegal, T. (2007). Novel Mechanism whereby Nuclear Factor {kappa}B Mediates DNA Damage Repair through Regulation of O6-Methylguanine-DNA-Methyltransferase. Cancer Res. 67: 8952-8959 [Abstract] [Full Text]  
• Riesterer, O., Milas, L., Ang, K. K. (2007). Use of Molecular Biomarkers for Predicting the Response to Radiotherapy With or Without Chemotherapy. JCO 25: 4075-4083 [Abstract] [Full Text]  
• Stupp, R., Hegi, M. E., Gilbert, M. R., Chakravarti, A. (2007). Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions. JCO 25: 4127-4136 [Abstract] [Full Text]  
• Stupp, R., Hegi, M. E. (2007). In Reply. JCO 25: 3550-3551 [Full Text]  
• Lonning, P., Knappskog, S, Staalesen, V, Chrisanthar, R, Lillehaug, J. (2007). Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol 18: 1293-1306 [Abstract] [Full Text]  
• Kao, G. D., Jiang, Z., Fernandes, A. M., Gupta, A. K., Maity, A. (2007). Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation. J. Biol. Chem. 282: 21206-21212 [Abstract] [Full Text]  
• Mikeska, T., Bock, C., El-Maarri, O., Hubner, A., Ehrentraut, D., Schramm, J., Felsberg, J., Kahl, P., Buttner, R., Pietsch, T., Waha, A. (2007). Optimization of Quantitative MGMT Promoter Methylation Analysis Using Pyrosequencing and Combined Bisulfite Restriction Analysis. J. Mol. Diagn. 9: 368-381 [Abstract] [Full Text]  
• Ranson, M., Hersey, P., Thompson, D., Beith, J., McArthur, G. A., Haydon, A., Davis, I. D., Kefford, R. F., Mortimer, P., Harris, P. A., Baka, S., Seebaran, A., Sabharwal, A., Watson, A. J., Margison, G. P., Middleton, M. R. (2007). Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous Melanoma. JCO 25: 2540-2545 [Abstract] [Full Text]  
• French, P. J., Peeters, J., Horsman, S., Duijm, E., Siccama, I., van den Bent, M. J., Luider, T. M., Kros, J. M., van der Spek, P., Sillevis Smitt, P. A. (2007). Identification of Differentially Regulated Splice Variants and Novel Exons in Glial Brain Tumors Using Exon Expression Arrays. Cancer Res. 67: 5635-5642 [Abstract] [Full Text]  
• Ekeblad, S., Sundin, A., Janson, E. T., Welin, S., Granberg, D., Kindmark, H., Dunder, K., Kozlovacki, G., Orlefors, H., Sigurd, M., Oberg, K., Eriksson, B., Skogseid, B. (2007). Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors. Clin. Cancer Res. 13: 2986-2991 [Abstract] [Full Text]  
• Jiang, Z., Pore, N., Cerniglia, G. J., Mick, R., Georgescu, M.-M., Bernhard, E. J., Hahn, S. M., Gupta, A. K., Maity, A. (2007). Phosphatase and Tensin Homologue Deficiency in Glioblastoma Confers Resistance to Radiation and Temozolomide that Is Reversed by the Protease Inhibitor Nelfinavir. Cancer Res. 67: 4467-4473 [Abstract] [Full Text]  
• Ohgaki, H., Kleihues, P. (2007). Genetic Pathways to Primary and Secondary Glioblastoma. Am. J. Pathol. 170: 1445-1453 [Abstract] [Full Text]  
• Eoli, M., Menghi, F., Bruzzone, M. G., De Simone, T., Valletta, L., Pollo, B., Bissola, L., Silvani, A., Bianchessi, D., D'Incerti, L., Filippini, G., Broggi, G., Boiardi, A., Finocchiaro, G. (2007). Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival. Clin. Cancer Res. 13: 2606-2613 [Abstract] [Full Text]  
• Stupp, R., Hegi, M. E. (2007). Methylguanine Methyltransferase Testing in Glioblastoma: When and How?. JCO 25: 1459-1460 [Full Text]  
• Chinot, O. L., Barrie, M., Fuentes, S., Eudes, N., Lancelot, S., Metellus, P., Muracciole, X., Braguer, D., Ouafik, L., Martin, P.-M., Dufour, H., Figarella-Branger, D. (2007). Correlation Between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolomide. JCO 25: 1470-1475 [Abstract] [Full Text]  
• Ngo, T.-T B., Peng, T., Liang, X.-J., Akeju, O., Pastorino, S., Zhang, W., Kotliarov, Y., Zenklusen, J. C., Fine, H. A., Maric, D., Wen, P. Y., De Girolami, U., Black, P. McL., Wu, W. W., Shen, R.-F., Jeffries, N. O., Kang, D.-W., Park, J. K. (2007). The 1p-Encoded Protein Stathmin and Resistance of Malignant Gliomas to Nitrosoureas. JNCI J Natl Cancer Inst 99: 639-652 [Abstract] [Full Text]  
• Brena, R. M., Costello, J. F. (2007). Genome-epigenome interactions in cancer. Hum Mol Genet 16: R96-R105 [Abstract] [Full Text]  
• Cahill, D. P., Levine, K. K., Betensky, R. A., Codd, P. J., Romany, C. A., Reavie, L. B., Batchelor, T. T., Futreal, P. A., Stratton, M. R., Curry, W. T., Iafrate, A. J., Louis, D. N. (2007). Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment. Clin. Cancer Res. 13: 2038-2045 [Abstract] [Full Text]  
• Yates, D. R., Rehman, I., Abbod, M. F., Meuth, M., Cross, S. S., Linkens, D. A., Hamdy, F. C., Catto, J. W.F. (2007). Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer. Clin. Cancer Res. 13: 2046-2053 [Abstract] [Full Text]  
• Wojdacz, T. K., Dobrovic, A. (2007). Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 35: e41-e41 [Abstract] [Full Text]  
• Lavon, I., Zrihan, D., Zelikovitch, B., Fellig, Y., Fuchs, D., Soffer, D., Siegal, T. (2007). Longitudinal Assessment of Genetic and Epigenetic Markers in Oligodendrogliomas. Clin. Cancer Res. 13: 1429-1437 [Abstract] [Full Text]  
• Weingart, J., Grossman, S. A., Carson, K. A., Fisher, J. D., Delaney, S. M., Rosenblum, M. L., Olivi, A., Judy, K., Tatter, S. B., Dolan, M. E. (2007). Phase I Trial of Polifeprosan 20 With Carmustine Implant Plus Continuous Infusion of Intravenous O6-Benzylguanine in Adults With Recurrent Malignant Glioma: New Approaches to Brain Tumor Therapy CNS Consortium Trial. JCO 25: 399-404 [Abstract] [Full Text]  
• Samuels, M. A. (2007). Update in Neurology. ANN INTERN MED 146: 128-132 [Full Text]  
• Blough, M. D., Zlatescu, M. C., Cairncross, J. G. (2007). O6-Methylguanine-DNA Methyltransferase Regulation by p53 in Astrocytic Cells. Cancer Res. 67: 580-584 [Abstract] [Full Text]  
• Rubie, H., Chisholm, J., Defachelles, A. S., Morland, B., Munzer, C., Valteau-Couanet, D., Mosseri, V., Bergeron, C., Weston, C., Coze, C., Auvrignon, A., Djafari, L., Hobson, R., Baunin, C., Dickinson, F., Brisse, H., McHugh, K., Biassoni, L., Giammarile, F., Vassal, G. (2006). Phase II Study of Temozolomide in Relapsed or Refractory High-Risk Neuroblastoma: A Joint Societe Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group New Agents Group Study. JCO 24: 5259-5264 [Abstract] [Full Text]  
• Brandes, A. A., Tosoni, A., Cavallo, G., Reni, M., Franceschi, E., Bonaldi, L., Bertorelle, R., Gardiman, M., Ghimenton, C., Iuzzolino, P., Pession, A., Blatt, V., Ermani, M. (2006). Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study. JCO 24: 4746-4753 [Abstract] [Full Text]  
• Maxwell, J. A., Johnson, S. P., Quinn, J. A., McLendon, R. E., Ali-Osman, F., Friedman, A. H., Herndon, J. E. II, Bierau, K., Bigley, J., Bigner, D. D., Friedman, H. S. (2006). Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.. Molecular Cancer Therapeutics 5: 2531-2539 [Abstract] [Full Text]  
• Hormigo, A., Gu, B., Karimi, S., Riedel, E., Panageas, K. S., Edgar, M. A., Tanwar, M. K., Rao, J. S., Fleisher, M., DeAngelis, L. M., Holland, E. C. (2006). YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas.. Clin. Cancer Res. 12: 5698-5704 [Abstract] [Full Text]  
• Herrlinger, U., Rieger, J., Koch, D., Loeser, S., Blaschke, B., Kortmann, R.-D., Steinbach, J. P., Hundsberger, T., Wick, W., Meyermann, R., Tan, T.-C., Sommer, C., Bamberg, M., Reifenberger, G., Weller, M. (2006). Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03. JCO 24: 4412-4417 [Abstract] [Full Text]  
• Cadieux, B., Ching, T.-T., VandenBerg, S. R., Costello, J. F. (2006). Genome-wide Hypomethylation in Human Glioblastomas Associated with Specific Copy Number Alteration, Methylenetetrahydrofolate Reductase Allele Status, and Increased Proliferation.. Cancer Res. 66: 8469-8476 [Abstract] [Full Text]  
• Auger, N., Thillet, J., Wanherdrick, K., Idbaih, A., Legrier, M.-E., Dutrillaux, B., Sanson, M., Poupon, M.-F. (2006). Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line.. Molecular Cancer Therapeutics 5: 2182-2192 [Abstract] [Full Text]  
• Kim, T.-Y., Zhong, S., Fields, C. R., Kim, J. H., Robertson, K. D. (2006). Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma.. Cancer Res. 66: 7490-7501 [Abstract] [Full Text]  
• Olesen, J., Baker, M. G, Freund, T., di Luca, M., Mendlewicz, J., Ragan, I., Westphal, M. (2006). Consensus document on European brain research. J. Neurol. Neurosurg. Psychiatry 77: i1-i49 [Abstract] [Full Text]  
• Chakravarti, A., Erkkinen, M. G., Nestler, U., Stupp, R., Mehta, M., Aldape, K., Gilbert, M. R., Black, P. McL., Loeffler, J. S. (2006). Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms. Clin. Cancer Res. 12: 4738-4746 [Abstract] [Full Text]  
• Pollack, I. F., Hamilton, R. L., Sobol, R. W., Burnham, J., Yates, A. J., Holmes, E. J., Zhou, T., Finlay, J. L. (2006). O6-Methylguanine-DNA Methyltransferase Expression Strongly Correlates With Outcome in Childhood Malignant Gliomas: Results From the CCG-945 Cohort. JCO 24: 3431-3437 [Abstract] [Full Text]  
• Foltz, G., Ryu, G.-Y., Yoon, J.-G., Nelson, T., Fahey, J., Frakes, A., Lee, H., Field, L., Zander, K., Sibenaller, Z., Ryken, T. C., Vibhakar, R., Hood, L., Madan, A. (2006). Genome-Wide Analysis of Epigenetic Silencing Identifies BEX1 and BEX2 as Candidate Tumor Suppressor Genes in Malignant Glioma.. Cancer Res. 66: 6665-6674 [Abstract] [Full Text]  
• van den Bent, M. J., Carpentier, A. F., Brandes, A. A., Sanson, M., Taphoorn, M. J.B., Bernsen, H. J.J.A., Frenay, M., Tijssen, C. C., Grisold, W., Sipos, L., Haaxma-Reiche, H., Kros, J. M., van Kouwenhoven, M. C.M., Vecht, C. J., Allgeier, A., Lacombe, D., Gorlia, T. (2006). Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial. JCO 24: 2715-2722 [Abstract] [Full Text]  
• Kneifel, S., Cordier, D., Good, S., Ionescu, M. C.S., Ghaffari, A., Hofer, S., Kretzschmar, M., Tolnay, M., Apostolidis, C., Waser, B., Arnold, M., Mueller-Brand, J., Maecke, H. R., Reubi, J. C., Merlo, A. (2006). Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P.. Clin. Cancer Res. 12: 3843-3850 [Abstract] [Full Text]  
• Mirimanoff, R.-O., Gorlia, T., Mason, W., Van den Bent, M. J., Kortmann, R.-D., Fisher, B., Reni, M., Brandes, A. A., Curschmann, J., Villa, S., Cairncross, G., Allgeier, A., Lacombe, D., Stupp, R. (2006). Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial. JCO 24: 2563-2569 [Abstract] [Full Text]  
• Ogino, S., Kawasaki, T., Brahmandam, M., Cantor, M., Kirkner, G. J., Spiegelman, D., Makrigiorgos, G. M., Weisenberger, D. J., Laird, P. W., Loda, M., Fuchs, C. S. (2006). Precision and Performance Characteristics of Bisulfite Conversion and Real-Time PCR (MethyLight) for Quantitative DNA Methylation Analysis. J. Mol. Diagn. 8: 209-217 [Abstract] [Full Text]  
• Hunter, C., Smith, R., Cahill, D. P., Stephens, P., Stevens, C., Teague, J., Greenman, C., Edkins, S., Bignell, G., Davies, H., O'Meara, S., Parker, A., Avis, T., Barthorpe, S., Brackenbury, L., Buck, G., Butler, A., Clements, J., Cole, J., Dicks, E., Forbes, S., Gorton, M., Gray, K., Halliday, K., Harrison, R., Hills, K., Hinton, J., Jenkinson, A., Jones, D., Kosmidou, V., Laman, R., Lugg, R., Menzies, A., Perry, J., Petty, R., Raine, K., Richardson, D., Shepherd, R., Small, A., Solomon, H., Tofts, C., Varian, J., West, S., Widaa, S., Yates, A., Easton, D. F., Riggins, G., Roy, J. E., Levine, K. K., Mueller, W., Batchelor, T. T., Louis, D. N., Stratton, M. R., Futreal, P. A., Wooster, R. (2006). A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy.. Cancer Res. 66: 3987-3991 [Abstract] [Full Text]  
• Jaeckle, K. A., Ballman, K. V., Rao, R. D., Jenkins, R. B., Buckner, J. C. (2006). Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response. JCO 24: 1246-1252 [Abstract] [Full Text]  
• Reardon, D. A., Rich, J. N., Friedman, H. S., Bigner, D. D. (2006). Recent Advances in the Treatment of Malignant Astrocytoma. JCO 24: 1253-1265 [Abstract] [Full Text]  
• Butowski, N. A., Sneed, P. K., Chang, S. M. (2006). Diagnosis and Treatment of Recurrent High-Grade Astrocytoma. JCO 24: 1273-1280 [Abstract] [Full Text]  
• Gilbert, M. R. (2006). New treatments for malignant gliomas: careful evaluation and cautious optimism required.. ANN INTERN MED 144: 371-373 [Full Text]  
• Henson, J. W. (2006). Treatment of glioblastoma multiforme: a new standard.. Arch Neurol 63: 337-341 [Full Text]  
• Stupp, R., Hegi, M. E., van den Bent, M. J., Mason, W. P., Weller, M., Mirimanoff, R. O., Cairncross, J. G., on behalf of the European Organisation for Researc, (2006). Changing paradigms--an update on the multidisciplinary management of malignant glioma.. The Oncologist 11: 165-180 [Abstract] [Full Text]  
• Liu, L., Gerson, S. L. (2006). Targeted Modulation of MGMT: Clinical Implications. Clin. Cancer Res. 12: 328-331 [Abstract] [Full Text]  
• Bredel, M., Bredel, C., Juric, D., Duran, G. E., Yu, R. X., Harsh, G. R., Vogel, H., Recht, L. D., Scheck, A. C., Sikic, B. I. (2006). Tumor Necrosis Factor-{alpha}-Induced Protein 3 As a Putative Regulator of Nuclear Factor-{kappa}B-Mediated Resistance to O6-Alkylating Agents in Human Glioblastomas. JCO 24: 274-287 [Abstract] [Full Text]  
• Herbst, R. S., Bajorin, D. F., Bleiberg, H., Blum, D., Hao, D., Johnson, B. E., Ozols, R. F., Demetri, G. D., Ganz, P. A., Kris, M. G., Levin, B., Markman, M., Raghavan, D., Reaman, G. H., Sawaya, R., Schuchter, L. M., Sweetenham, J. W., Vahdat, L. T., Vokes, E. E., Winn, R. J., Mayer, R. J. (2006). Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening--A Report From the American Society of Clinical Oncology. JCO 24: 190-205 [Abstract] [Full Text]  
• KAO, J., ROSENSTEIN, B. S., PETERS, S., MILANO, M. T., KRON, S. J. (2005). Cellular Response to DNA Damage. Ann. N. Y. Acad. Sci. 1066: 243-258 [Abstract] [Full Text]  
• Hansen, R. J., Nagasubramanian, R., Delaney, S. M., Cherian, M. M., Lin, S., Kogan, S. C., Dolan, M. E. (2005). Role of O6-Alkylguanine-DNA Alkyltransferase in Protecting against 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-Induced Long-Term Toxicities. J. Pharmacol. Exp. Ther. 315: 1247-1255 [Abstract] [Full Text]  
• Hamstra, D. A., Chenevert, T. L., Moffat, B. A., Johnson, T. D., Meyer, C. R., Mukherji, S. K., Quint, D. J., Gebarski, S. S., Fan, X., Tsien, C. I., Lawrence, T. S., Junck, L., Rehemtulla, A., Ross, B. D. (2005). Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc. Natl. Acad. Sci. USA 102: 16759-16764 [Abstract] [Full Text]